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In vivo radionuclide generators make complex combinations of physical and chemical properties available for medical diagnostics
and therapy. Perhaps the best-known in vivo generator is 212Pb/212Bi, which takes advantage of the extended half-life of 212Pb
to execute a targeted delivery of the therapeutic short-lived 𝛼-emitter 212Bi. Often, as in the case of 81Rb/81Kr, chemical changes
resulting from the transmutation of the parent are relied upon for diagnostic value. In other instances such as with extended alpha
decay chains, chemical changes may lead to unwanted consequences. This article reviews some common and not-so-common in
vivo generators with the purpose of understanding their value in medicine and medical research. This is currently relevant in light
of a recent push for alpha emitters in targeted therapies, which often come with extended decay chains.
1. Introduction
The medical potential of radiation has been recognized
nearly since the discovery of radioactivity. In the very first
medical applications, isolated samples of naturally occurring
𝛼-emitters were used for the treatment of cancer (e.g., [1]
or in review [2]). In these cases, the therapeutic benefits (or
detriments) were partially due to the radioactive decay prod-
ucts, termed daughters, of the initially injected radionuclides,
termed parents. By producing the daughter in the body,
medically administered parents act as “in vivo generators.”
The term in vivo generator first appears in a confer-
ence abstract by Mausner et al. [3], discussing the use
of targeted monoclonal antibodies (mAbs) with long-lived
parent radionuclides that decay into short-lived daughter
radionuclides. The concept was to combine the long half-
life of the parent with the high decay energy of the daughter
to achieve high-dose targeted radiotherapy. By introducing
in vivo generators they proposed to overcome a physical
limitation to radionuclide therapy where nuclides with high
decay energies tend to have half-lives that are too short
for targeted systemic therapies. Changes in biochemical
interactions following decay are also exploited through the
use of in vivo generators, exemplified by the 81Rb/81mKr
in vivo generator system. There the parent 81Rb+ (𝑡1/2 =
4.3 h) accumulates in cells due to its chemical similarity
to K+. Following a decay, the inert metastable daughter,
81mKr (𝑡1/2 = 13 s), leaves the cells via diffusion, allowing
quantification of tissue perfusion [4].
These examples highlight the two main applications of
in vivo generators, which are the same as the in vivo uses
of radioactivity: diagnosis and therapy (briefly reviewed by
Ro¨sch and Knapp 2003 [5]). Overall, the advantage of in vivo
generators is to combine nuclear and chemical properties of
the parent and daughter nuclides to better diagnose or treat
physiological conditions. This review is intended to cover
many of the in vivo generators that have been used clinically
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and preclinically for imaging and therapy. The consequences
and considerations of their use are also discussed, especially
in light of the therapeutic 𝛼-emitters which have extended
decay chains. Ideally highlighting the unique advantages
afforded by in vivo generators will inspire future applications
and expand the palette of nuclear and chemical properties
available for medicine.
2. Release and Redistribution of
Daughter Radionuclides
The most important consideration when employing an in
vivo generator is the chemical consequence of the parent
decay. In many cases, the chemical change from one atomic
number to another is enough to cause a drastic difference
between parent and daughter chemistry (e.g., a transition
from alkali rubidium to noble krypton). However, even
when the parent and daughter have nearly identical chemical
behavior, as with transitions between lanthanides, there is
still a possibility for a chemical change due to the atomic
effects of nuclear decay. Molecular changes due to nuclear
reactions are known as Szilard-Chalmers reactions, originally
described by Szilard and Chalmers in 1934 as a means for
separating isotopes of iodine after the chemical disruptions
caused by neutron capture [6]. Since then there have been
several Szilard-Chalmers type reactions described for the
purpose of medical isotope production [7] and notably in
generator reactions (e.g., [8]).
When extending the concept to in vivo generators, it
is important to understand the circumstances that give rise
to a difference between the parent and daughter chemistry.
This is because, in most cases, medical radionuclides are
used as labels on chemically specific “targeting” molecules
such as peptides, antibodies, or receptor- and transporter-
specific small molecules. When using an in vivo generator
in these targeted systems, there are two opportunities for the
daughter to separate from the parent, either as a result of
the elemental differences between the parent and daughter
or as a consequence of the physical and chemical disruption
caused by the nuclear decay itself. Depending on the intended
use of the generator, dislocation of the daughter from the
targeting molecule can be an advantage or a disadvantage,
and therefore it is important to understand when dislocation
is expected and to understand the consequences of that
dislocation.
In a series of papers, Zeevaart et al. described the
physical considerations for when a chemical rearrangement
is expected [9–12]. Their first approach was to look at
whether or not the recoil of the daughter nucleus after
𝛽-decay, accounting for both the emitted neutrino and
electron, could provide sufficient energy to dislodge the
daughter from strong polydentate chelates. The general
conclusion from their calculations is that in most instances
the binding energy of the chelate is too high to be overcome
by the small amount of energy involved in nuclear recoil.
For example, for the pair 90Sr/90Y complexed to 1,4,7,10
tetraazacyclododecane 1,4,7,10 tetraacetic acid (DOTA), only
1% of all 𝛽-decays led to a dislocation of the daughter 90Y
[10]. Internal transition (IT) decays are likewise consistent
with stable chelation being retained under low energy
recoil, for example, with the transition of 44mSc to 44gSc
leading to no observed dislocation of the daughter atom
from stable chelate structures with DOTA [13]. For other
decay modes, however, the physical recoil energy can far
exceed the binding energy. This is the case with 213Bi 𝛼-
decay where the recoil is on the order of 100 keV, compared
to the binding energy of the daughter Pb(II) with the
ubiquitous chelators DOTA or its amide derivative: 2-(4-
isothiocyanotobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra-(2-car-
bamonyl methyl)-cyclododecane (TCMC) of a few electron
volts.
Electron capture (EC) decays are also efficient at releasing
daughter nuclides from strong chelates, as observed with
140Nd and 134Ce. In these cases the Auger electron cascade
following nuclear absorption of an inner shell electron causes
atomic rearrangements that circumvent chelation. In similar
Auger processes, such as the decay of 165Er, it is calculated
that the autoionization process following transition to 165Ho
leaves the daughter in an unstable and highly oxidized state,
on average losing 7.6 electrons per decay [14]. Experimental
observations of the EC decay of radiolanthanides are con-
sistent with the conclusion that the daughters do not retain
the parents’ chemical state after the loss of so many electrons
[8].The same conclusion holds true for the similar process of
internal conversion (IC). For example, in the decay of DOTA-
bound 166Dy, 72% of all decays lead to an IC induced Auger
cascade, and consistently 72% of daughter 166Ho atoms are
found free from DOTA [10], showing that the delocalization
is a Szilard-Chalmers reaction. As discussed by Zeevaart et
al. [10] and Nath et al. [15], one possibility of counteracting
the Auger-induced dislocation of the daughter atoms is to
conjugate the metal ions via a ligand with an extensive
delocalized 𝜋-electron system, such as heme. Such ligands
are capable of quenching the so-called “Coulomb explosion”
by transferring electrons to the metal center with comparable
time scales to the Auger cascade.
Overall, the general rule to predict delocalization in in
vivo generators is that, when the daughter and parent nuclide
can both form stable complexes with the bioconjugate-
chelate moiety, parent EC, IC, and alpha decays will all cause
dislocation of the daughter, whereas 𝛽 and IT decays tend to
leave the daughter in the parent’s chemical state.
3. Possible In Vivo Generators
Table 1 gives a list of some in vivo generators adapted from
Ro¨sch and Knapp [5]. Data were obtained from the National
Nuclear Data Center [16].
4. In Vivo Generators for Diagnostics
4.1. General Principals. As stated above, the main purpose
for applying in vivo generators for imaging and diagnostics
is either to combine the long half-life of a parent nuclide
with a short-lived daughter’s diagnostic emission or to take
advantage of a chemical change following the parent decay
that can give information about the site of parent decay. The
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Table 1
Parent Decay 𝑡1/2 Daughter Decay 𝑡1/2 Use
Diagnostics
44mSc IT 60 h 44Sc 𝛽+ 4 h PET
52Fe EC/𝛽+ 8.3 h 52mMn 𝛽+ 21min PET
62Zn EC/𝛽+ 9.2 h 62Cu 𝛽+ 9.7min PET
81Rb EC 4.6 h 81mKr IT 13 s SPECT
99Mo 𝛽− 66 h 99mTc IT 6.0 h SPECT
134Ce EC 3.2 d 134La 𝛽+ 6.5min PET
140Nd EC 3.4 d 140Pr 𝛽+ 3.4min PET
Therapy
66Ni 𝛽− 2.3 d 66Cu 𝛽− 5.1min 𝛽
103Pd EC 16 d 103mRh EC 46min Auger
112Pd 𝛽− 21.04 h 112Ag 𝛽− 3.14 h 𝛽
166Dy 𝛽− 3.4 d 166Ho 𝛽− 1.12 d 𝛽
212Pb 𝛽− 10.64 h 212Bi a 1.01 h 𝛼
213Bi 𝛼 45.6min 209Pb 𝛽− 3.3 h 𝛼
223Ra 𝛼 11.4 d Chain 𝛼
225Ac 𝛼 10.0 d Chain 𝛼
227Th 𝛼 18.7 d Chain 𝛼
former is conceptually simple and is only complicated by the
potential chemical change after decay. One great example
where there is little to no concern over a chemical change
after decay is with the use of 44mSc, which decays via IT
into its positron emitting daughter 44gSc without changing its
chemical state [13]. Thereby it becomes possible to consider
44mSc as simply a long-lived positron emission tomography
(PET) radionuclide. Despite the simplicity, this development
relates to the critical arguments presented by Mausner et al.:
there is an inverse relationship between the energy available
for weak force mediated decays and nuclear lifetimes [3]. On
the proton rich side of the chart of the nuclides, this fact
along with the positron rest mass cutoff and the competitive
decay mode of EC severely limits the number of long-lived
𝛽+-emitters. This results in a shortage of long-lived PET
radionuclides. To put it into perspective, the number of 𝛽+-
emitters with positron branching over 10% with half-lives
between 12 h and 10 d is 10, whereas on the neutron rich
side of the chart there are over 70 nuclides that undergo
𝛽− decay with the same half-life constraints [16]. Therefore,
adding longer-lived in vivo generators of 𝛽+-emitters makes
a needed enhancement to the list of available nuclides for
PET. Other PET in vivo generator pairs offer similarly long
half-lives and chemistry as 44mSc, namely, 134Ce and 140Nd,
but these generators have the added trait that the daughter
nuclides do not retain the parent chemical form but are freed
after the initial EC decay [8]. Free radiometals can have
misleading effects on PET and SPECT quantifications, as they
often accumulate in disease sites and other tissues [17–20].
Not all of the diagnostic in vivo generators presented in
Table 1 have been used in clinical or preclinical studies, but
several have led to interesting results. Below are examples
of some of the uses of diagnostic in vivo generators. The
description starts with one of the first in vivo generators,
81Rb/81mKr, that relies on the chemical change transitioning
from rubidium to krypton to achieve the desired diagnostic
information.
4.2. 81Rb/81𝑚Kr. One of the first purposeful uses of an in vivo
generator is 81Rb/81mKr for imaging perfusion.Originally, the
system was developed as an external generator of gaseous
81mKr to be inhaled for pulmonary ventilation studies (e.g.,
[21, 22]). The 190 keV gamma from 81mKr is well attuned for
SPECT and gamma cameras, and the short half-life allows
rapid repeat investigations of short physiological processes.
One of the most important uses of 81mKr, however, arises
from the in vivo generator that results following injection of
the parent 81Rb.
Rubidium mimics potassium and accumulates in cells,
whereas krypton is inert, freely diffuses over cell membranes,
and is carried away by blood flow. In 1971 Jones andMatthews
[4] introduced the concept of measuring tissue perfusion
with the in vivo generator by determining the rate at which
81mKr is carried away from 81Rb containing tissues: the rate
being proportional to perfusion. After a first pass through
the lungs, the gaseous krypton leaves the blood stream.
In practice, their method simply requires simultaneously
quantifying 81mKr and 81Rb in an organ of interest, which
they show to be readily achievedwith a sodium iodide or high
purity germanium detector. They go on to show a proof-of-
concept measurement of perfusion in a mock system where
81Rb is trapped on cation exchange resin, and 81mKr is washed
away by controlled flow of deionized water over the resin.
Several other examples of the use of 81Rb/81mKr as an in vivo
generator appear in the literature [23–25].
4.3. 52Fe/52𝑚Mn. The 52Fe/52mMn in vivo generator poten-
tially provides a wealth of biological information, although it
is hindered by the fact that both the parent and the daughter
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emit positrons. As PET relies upon detection of annihilation
photons at 511 keV, it is impossible for traditional PET to
distinguish between 52Fe and 52mMn decays. The respective
positron branches are 55.5% for 52Fe and 96.8% for 52mMn.
Despite this difficulty, the pair remains desirable, or at least
unavoidable, as a PET tracer for the distribution of biological
iron. Iron transport in the body is particularly important as
improper iron transport is linked to a number of diseases,
and tracking the distribution of iron in supplements and
remedies is important for drug development [26]. However,
the only 𝛽+-emitting isotope of iron with an appropriate half-
life for biological tracing is 52Fe. In order to disentangle the
contribution of 52mMn to iron tracing by 52Fe, Lubberink
and coworkers evaluated clinical data from injections of
a sucrose-stabilized 52Fe along with blood sampling and
determined tissue-dependent correction factors [27]. A sim-
ilar approach was taken by Calonder et al. to investigate
iron transport across the blood brain barrier in monkeys
[28]. Those techniques were further adapted for a clinical
evaluation of iron trafficking in patientswithWilson’s disease,
a condition related to improper metal ion transport [29].
4.4. 140Nd/Pr, 134Ce/La. 140Nd and 134Ce have nearly iden-
tical properties: both are light lanthanides, have roughly
3 d half-lives, and decay purely by EC into short-lived 𝛽+-
emitting daughters. These nuclides are discussed for their
therapeutic potential due to Auger emission from the parent
decay followed by high-energy𝛽 emission from the daughters
[30, 31]. The drawback of these pairs is that the parents’
EC decay releases the daughters from targeting vectors.
Dosimetrically, this is problematic because the high-energy
positronsmay be emitted away from targeted cells. Lubberink
et al. assert that, in cases where targeting vectors are cellularly
internalized, the daughter decays will occur within the
targeted cell [31]. In preclinical animal models, one way to
determine if the decays of the daughter occur in the same
tissues as the parent is by PET imaging before and after
sacrificing the animal. A premortem image will show the
result of biological redistribution of the daughter, and the
postmortem image will reveal the parent distribution. In
cases where the daughter has high access to blood flow, a high
level of redistribution would occur. When targeted tissues
retain the daughters, this would indicate that the targeting
vector would be appropriate for radiotherapy with in vivo
generators. Contrastingly, when the targeted tissues do not
retain the daughters, it may be appropriate to implement
pretargeting (e.g., [32]) as the redistribution of the daughters
could indicate that the targeting vector is accessible from the
blood stream.
4.5. 62Zn/62Cu. Similar to 52Fe/52mMn’s role as a PET pair
for tracing iron, the 62Zn/62Cu system is potentially useful as
a tracer for biological Zn. Other uses include immunoPET
[33] or small molecule imaging [34, 35]. In these cases, the
positron branch in the parent is not as pronounced, only
8%. Therefore, PET imaging with the in vivo generator is
dominated by positrons emitted by 62Cu, which has a 10-
minute half-life in which to redistribute. More investigation
into the consequences of redistribution would aid in the
evaluation of 62Zn/62Cu as a PET radiolabel.
5. Therapeutic In Vivo Generators
5.1. General Principals. Targeted radiotherapy can be defined
as the use of radiolabeled molecules as a means to deliver a
cytotoxic amount of radiation to a disease site to treat a patho-
logical condition (i.e., cancer, rheumatoid arthritis) [36].
When radiation interacts with biological tissues its energy
is absorbed by the surrounding tissues and if sufficient, an
orbital electron is ejected resulting in ionization. The ionized
molecules (typically water) result in the formation of free
radicals which can then cause damage to cellular components
(e.g., DNA) resulting in cell death [37]. This process takes
advantage of high-energy emissions such as 𝛼-particles, 𝛽-
particles, or lower energy Auger electrons as a means to
destroy cellular DNA.
Ultimately the goal of radiotherapy is to deliver a maxi-
mum radiation dose to the unhealthy cells while minimizing
the radiation endured by healthy cells. One important factor
that must be considered is the linear energy transfer (LET),
which describes the ratio between the amount of energy
transferred and the distance travelled by the radiation prod-
uct. An advantage of 𝛼-emitters is that they possess a high
LET when compared to 𝛽-emitters. For instances, 𝛼-particles
can have LET values ranging from 80 to 100 keV/𝜇m while
𝛽-particles have an LET of 0.2 keV/𝜇m [38]. Given these
constraints it is important to consider the targeting vector
used when developing targeted radiotherapeutic agents. Cri-
teria such as selectivity, specificity, and internalization need
to be considered as well as the tumor size in the case of
oncological disorders. The range of 𝛼-particle can be as little
as a few cell diameters (40–80 𝜇m) making it possible to
target small cell clusters, micrometastases, and single cells
[38, 39]. On the other hand,𝛽-particle emissions have amuch
longer path range (0.8–5mm) and so the radiation is not
necessarily deposited in the same location as the targeting
vector, which can result in damage to the surrounding healthy
tissue [38, 40].
Despite this, the majority of targeted radiotherapeutic
agents used in the clinic are 𝛽-emitters [41]. In fact in 2013 the
first 𝛼-emitting radioisotope that was approved for routine
clinical use was 223Ra which has received approval from
the Food and Drug Association (FDA) and the European
Commission (EC) [42]. This discrepancy is likely due to
the fact that most 𝛼-emitting radionuclides possess half-lives
that are not suitable for clinical applications [36]. First the
short half-lives limit the use targeting vectors that have long
blood circulation times such as mAbs. Conversely isotopes
with longer half-lives can be detrimental due to their high
LET where there is a greater risk for toxicity as a result of
irradiating healthy tissues during circulation. One solution is
to perform direct injections into the diseased tissue; however,
this is not always possible in the case of micrometastases. A
way to circumvent this issue is to use in vivo generators.
An advantage of the in vivo generator system when
applied to radiotherapy is that the longer-lived parent isotope
can be cleared from blood circulation and healthy tissues
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while its high LET daughters will accumulate in the diseased
tissue. This will result in a lower radiation dose to the
healthy tissues and maximize the radiation dose at the target
site. In particular, the amount of radioactivity administered
can be minimized [39]. The challenges encountered during
the use of in vivo generators for radiotherapy are similar
to those encountered for diagnostic imaging. Achieving
adequate specific activity; incorporating ligands that form
stable complexes with both parent and daughter isotopes; and
reducing toxicity due to isotope loss as a result of recoil energy
during decay from parent to daughter are all issues that need
to be carefully considered before applying this approach [43].
Below are some examples of in vivo generators that have
been used for preclinical and clinical applications of radio-
therapy. While each pair suffers from some of the challenges
described above efforts have been made to overcome these
issues or take advantage of them for a positive outcome.
5.2. 212Pb/212Bi. Lead-212 has been investigated as an in vivo
generator for preclinical and clinical therapeutic applications
using a variety of mAb systems for direct targeting and
pretargeted radiotherapy [44–46]. Typically it has been
used to target the human epithermal growth factor receptor
(HER2) [45]. It undergoes 𝛽− decay producing 212Bi, 𝛼-
emitter with a half-life of 60min (Table 1). It is typically
incorporated into biological molecules using chelating lig-
ands such as DOTA and 2-(4-isothiocyanotobenzyl)-1,4,7,10-
tetraaza-1,4,7,10-tetra-(2-carbamonyl methyl)-cyclododec-
ane (TCMC) [47–49].
There have been difficulties in using this system due to
instability of the 212Bi daughter. It has been reported from
multiple studies that there is a 30–40% loss of 212Bi after
4 h due to the instability of the [212Bi]Bi-DOTA complex
[44, 49]. The thermodynamic stability of the parent Pb-
DOTA complex and the daughter Bi-DOTA complex was
tested using the 203Pb(II) and 206Bi(III) isotopes. Interestingly
rate of chemical exchange of these complexes was very
slow aqueous solutions (pH 4-10) [48]. The calculated recoil
energy of the 212Bi nucleus is not sufficient for breaking
a chemical bond and so the instability of the complex is
attributed to the poor kinetic stability of the 212Bi-DOTA
complex [39]. This instability is caused by the radiative
events that occur during isotopic decay, more specifically
the internal conversion of the 𝛾-rays emitted by the nuclide
[48]. It has also been shown that direct labeling of DOTA
conjugates with 212Bi is less efficient than other chelators
such as diethylenetriaminepentaacetic acid (DTPA) in the
presence of other complexing agents such as citric acid [50].
As a result any of the free 212Bi released will then be taken
into the nontargeted healthy tissues such as the kidneys [39].
Attempts have been made in producing ligands that serve
as stable chelators for both 212Pb and 212Bi. Ligands such as
dioctyl terephthalate (DOTP) have shown reassociation with
212Bi, yet 212Pb showed decreases stability at concentrations
below 1mM; therefore, its use is only suitable for tracers not
requiring high specific activity [39]. Nevertheless, 212Pb/212Bi
in vivo generators have been shown to be more effective
when applied to internalizing mAbs such as trastuzumab
when compared to noninternalizing or nonspecific mAbs.
One of the advantages of this system when compared to
the 𝛽−-emitting 90Y derivative is that the absorbed dose
at the tumor site is higher, taking advantage of the higher
LET of 𝛼-particles [45]. These promising preclinical results
have inspired further clinical studies. [212Pb]Pb-TCMC-
Trastuzumab has shown promise as a therapeutic agent over
𝛽-emitting isotopes following clinical evaluation [46].
5.3. 225Ac. Actinium-225 has shown promise as an in vivo
generator system in preclinical and clinical applications. It
is an isotope with a 10 d half-life that undergoes 𝛼-decay
and produces three 𝛼-emitting radioisotopes: 221Fr (𝑡1/2 =
4.9min), 217At (𝑡1/2 = 32.3ms), and
213Bi (𝑡1/2 = 46min)
[38]. Preclinical evaluation of 225Ac-DOTA-trastuzumab has
shown increased survival rates in murine models of ovar-
ian cancer [38]. Initially poor in vitro stability and low
radiochemical yields were observed when the mAb was first
functionalized with the DOTA ligand prior to radiolabeling.
This was overcome by applying a two-step approach where
the chelating ligand is first labeledwith themetal and then it is
conjugated to the mAb. Although high RCY yields (ca. 90%)
are achieved in the first step, conjugation to the antibody
is less efficient resulting in low apparent specific activity
[38]. This can be problematic where high specific activity is
required; however, in general 225Ac therapy is better suited
for internalized mAbs since the 221Fr isotope, for example,
is no longer able to be bound by the chelating ligand and
diffuses away from the targeting vector [38]. In analysis of
225Ac labeled mAb, lintuzumab has shown that renal toxicity
and an anemia could be a concern when using high doses in
nonhuman primates [51]. Clinical trials using low doses of
this agent are ongoing.
Another strategy to combat the diffusion of daughter
isotopes is to employ encapsulating liposomes, nanoparticles
to sequester the radioactivity at the target site. For example,
pegylated phosphatidylcholine-cholesterol liposomes of dif-
ferent sizes and charges were used to entrap 225Ac. The ionic
daughters produced following radioactive decay (Fr1+, At1−,
and Bi3+) are not expected to diffuse from the liposome. The
retention of the last produced daughter 213Bi wasmuch better
in the larger sized liposomes. The use of these liposomes is
better suited for locoregional therapy [52]. Perhaps a more
applicable strategy involves using multilayered encapsulating
nanoparticle that is then conjugated to amAb. In this strategy
the nanoparticle conjugate is able to contain the decay daugh-
ters of 225Ac while binding to antibody targets in vivo [53].
An advantage of these multifunctional nanoparticles is their
chemical properties for the containment, functionalization,
and imaging [53].
5.4. 227Th. Thorium-227 has demonstrated its utility as an
in vivo generator. One of its advantages is that it can be
readily obtained from a 227Ac generator at low costs. It has
a 18.7 d half-life and decays via 𝛽-particle emission forming
numerous 𝛼- and 𝛽-emitting isotopes: 223Ra, 219Rn, 215Po,
211Pb, 211Bi, and 207Tl. One of its most clinically relevant
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daughter isotopes is 223Ra. This bone seeking alkaline earth
metal has been clinically approved for radiotherapy due to
its ability to accumulate in the bone [54]. Since it dissociates
from ligand systems it cannot be used directly to label
targeting vectors but use of the 227Thinvivo generator is away
around this. Similar to the other in vivo generators discussed
thus far 227Th is best suited for internalizing targeting vectors
because the 223Ra isotope dissociates from ligand systems.
[227Th]Th-DOTA-trastuzumab has shown to be effective in
inhibiting the growth of breast cancer xenografts in mice, yet
it appears to be better suited for treating microscopic tumors
as opposed to fast growing macrometastases [47, 55].
5.5. 223Ra. Because of the bone seeking properties of the
alkaline earth metals Ra2+ has been used to treat bone
metastases as it behaves similarly to Ca2+. One of the most
recently clinically approved in vivo generators, used for
treating bone metastases, has been the 223Ra agent Xofigo
[56]. It is administered as solution of [223Ra]RaCl. The 223Ra
isotope has a half-life of 11.4 d and decays via 𝛼-particle
emission producing a number of 𝛼 and 𝛽− emitting daughter
isotopes (219Rn, 215Po, 211Pb, 211Bi, 211Po, and 207Tl) [54].
One of the challenges in using 𝛽−-emitters for treating bone
metastases is because their long radiation range damage to
the bone marrow is always a risk; therefore, their use has
been restricted to alleviating pain [54]. When compared to
the 𝛽− emitting alkaline earth metal 89Sr2+, 223Ra2+ displayed
much higher bone uptake in preclinical models [54]. The use
of 223Ra is an improvement over tracers using 224Ra since the
gaseous 222Rn daughter produced would diffuse away from
the target site [54].
5.6. 166Dy/166Ho. The applicability of the 166Dy/166Ho in vivo
generator system was first reported in 1994. Unlike the other
in vivo generators used for radiotherapy discussed thus far
the daughter isotope actually produces a 𝛽−-particle that is
useful for therapy. When the parent isotope 166Dy (𝑡1/2 =
81.5 h) is coordinated to the DTPA ligand system high serum
and in vivo stability is observed. This remains true of the
complex following decay to the Ho (𝑡1/2 = 26.6 h) daughter
[57]. When complexed with ethylenediaminetetramethylene
phosphonate (EDTMP) 166Dy has been shown to accumulate
in skeletal tissue and therefore can be applied for marrow
ablation [58].
6. Discussion and Conclusion
The development of in vivo generators as diagnostic and
therapeutic radiopharmaceuticals has expanded the scope of
radioisotopes used in nuclear medicine. Their use has served
as a way to employ radioisotopes that would have otherwise
been overlooked despite exhibiting desirable nuclear pro-
prieties for radio imaging and therapy (e.g., emission type,
emission energy, and LET in the case of therapy). One of the
many advantages of these systems is that they can circumvent
issues regarding short radiochemical half-lives by taking
advantage of the longer-lived parent isotope. From a practical
stand point this eliminates some of the time constraints that
exist in preparing shorter-lived radiopharmaceuticals (i.e.,
ensuring that an on-site cyclotron is present, implementing
short radiolabeling reactions, and limiting distances for
transportation). From a biological stand point this allows
for the use of slow clearing targeting vectors such as mAbs.
Direct labeling of a slow clearing targeting vector with a
short-lived therapeutic or diagnostic isotope would be futile
as the radioisotopewould decay before reaching its target site.
Whereas incorporating the parent isotope, where possible,
makes it possible to deliver the medically relevant short-lived
isotope to the target following radioactive decay. As a result
this method has resulted in the development of a number
of mAb based radiopharmaceuticals incorporating various in
vivo generator systems for preclinical and clinical use.
In addition to the challenges observed with short half-
lives, less commonly used radioisotopes often have chemical
proprieties that prevent them from being incorporated into
targeting vectors through typical chelation strategies. This is
evident in the case of 223Ra, which is typically used in its free
form due to its inability to form stable complexes with com-
monly used chelators. By using the in vivo generator 227Th,
the 223Ra daughter is produced at the target site following
radioactive decay. One must take care when applying this
approach, however, because this required the targeting vector
to be internalized to prevent diffusion of the daughter isotope
to other tissues.
This leads to one of the main challenges observed in
developing in vivo generators for clinical use. The instability
of the radiopharmaceutical that can result from the chemical
transformation of one element to another is something
that must be considered. Although this property has been
leveraged as a benefit when applied to internalizing targeting
vectors for therapeutic applications it can still be a detriment
especially for diagnostic imaging.When the daughter isotope
is released from the targeting vector it can diffuse into
nontargeted tissues resulting in confounding imaging results.
With the recent approval of Xofigo the medical commu-
nity is taking advantage of the use of𝛼-emitters as a therapeu-
tic tool. Continued efforts to test additional in vivo generators
in clinical trials are ongoing. By taking advantage of the
increased efficacy of 𝛼-emitting therapeutics in vivo gener-
ators have the advantage to improve therapeutic outcomes
over their 𝛽-emitting counterparts in radioimmunotherapy,
making this approach very promising for clinical oncology.
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